Novocure Limited - (NVCR) closed at $11.72 on November 12, 2026, down 2.3% from the previous close, on volume of 1,166,941 shares (30-day average 1,822,548).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Seagull With Call Spread | 20-Nov-2612 P : 16 C : 18 C | 1,500 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Fri, 13-Nov 11:30 AM ET)
NovoCure denied FDA approval of Optune Mya for brain metastases
Seeking Alpha News (Tue, 10-Nov 10:03 AM ET)
NovoCure Receives FDA Not Approvable Letter for Optune Mya
TipRanks (Mon, 9-Nov 7:38 AM ET)
Business Wire (Mon, 9-Nov 7:00 AM ET)
Novocure raises 2026 guidance after record quarterly revenue and 19% growth in active patients
Market Chameleon (Thu, 29-Oct 4:42 AM ET)
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Business Wire (Thu, 29-Oct 7:00 AM ET)
Business Wire (Wed, 28-Oct 7:00 AM ET)
Business Wire (Thu, 1-Oct 9:00 AM ET)
Novocure to Report Third Quarter 2026 Financial Results
Business Wire (Thu, 1-Oct 7:00 AM ET)
Novocure Announces Upcoming Investor Events
Business Wire (Wed, 2-Sep 7:00 AM ET)
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Novocure Limited - trades on the NASDAQ stock market under the symbol NVCR.
As of November 13, 2026, NVCR stock price climbed to $11.78 with 504,455 million shares trading.
NVCR has a beta of 1.28, meaning it tends to be more sensitive to market movements. NVCR has a correlation of 0.05 to the broad based SPY ETF.
NVCR has a market cap of $1.38 billion. This is considered a Small Cap stock.
Last quarter Novocure Limited - reported $193 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.14.
In the last 3 years, NVCR traded as high as $34.13 and as low as $9.82.
The top ETF exchange traded funds that NVCR belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.
NVCR has underperformed the market in the last year with a price return of +3.7% while the SPY ETF gained +11.4%. NVCR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.0% and -10.1%, respectively, while the SPY returned -2.2% and -2.1%, respectively.
NVCR support price is $11.28 and resistance is $12.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVCR shares will trade within this expected range on the day.
